nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2010

Cutaneous Manifestations of Dermatomyositis and Their Management

verfasst von: Jeffrey P. Callen

Erschienen in: Current Rheumatology Reports | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Dermatomyositis is a condition with pathognomonic and characteristic cutaneous lesions. This article describes the skin manifestations observed in patients with dermatomyositis, their differential diagnosis, their relationship to internal disease (particularly malignancy), and their management.

Callen JP, Wortmann RL: Dermatomyositis. Clin Dermatol 2006, 24:363–373.CrossRefPubMed

• Antiochos BB, Brown LA, Li Z, et al.: Malignancy is associated with dermatomyositis but not polymyositis in northern New England, USA. J Rheumatol 2009, 36:2704–2710. This study demonstrates that the presence of skin disease is an important risk factor for the presence of malignancy.CrossRefPubMed

Pachman LM, Abbott K, Sinacore JM, et al.: Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006, 148:247–253.CrossRefPubMed

• Bendewald MJ, Wetter DA, Li X, Davis MD: Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010, 146:26–30. This study demonstrated that amyopathic dermatomyositis occurs in about 20% of patients with dermatomyositis and that malignancy may occur in these patients as well.CrossRefPubMed

Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344–347.PubMedCrossRef

Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403–407.PubMed

Dourmishev L, Meffert H, Piazena H: Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed 2004, 20:230–234.CrossRefPubMed

Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887–894.CrossRefPubMed

Kasteler JS, Callen JP: Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 1994, 272:1939–1941CrossRefPubMed

10.

• Smith ES, Hallman JR, DeLuca AM, et al.: Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol 2009, 31:61–67. This report demonstrates that although there are subtle histopathologic differences between lupus erythematosus and dermatomyositis, these changes are not useful in distinguishing lupus from dermatomyositis in clinical practice.CrossRefPubMed

11.

Magro CM, Crowson AN: The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus. J Cutan Pathol 1997, 24:543–552.CrossRefPubMed

12.

• Magro CM, Segal JP, Neil Crowson A, Chadwick P: The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol 2009 Nov 4 (Epub ahead of print). This study demonstrates subtle differences between dermatomyositis and lupus erythematosus, but this testing is not likely to be applicable in clinical practice.

13.

Sontheimer RD: Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 2010, 146:76–80.CrossRefPubMed

14.

Hill CL, Zhang Y, Sigurgeirsson B, et al.: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96–100.CrossRefPubMed

15.

Lampropoulos CE, D’Cruz DP: Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis 2005, 64:1376–1377.CrossRefPubMed

16.

Woo TY, Callen JP, Voorhees JJ, et al.: Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984, 10:592–600.CrossRefPubMed

17.

Ang GC, Werth VP: Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005, 141:855–859.CrossRefPubMed

18.

Pelle MT, Callen JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002, 138:1231–1233.CrossRefPubMed

19.

Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD: The value of methotrexate in dermatomyositis. J Am Acad Dermatol 1998, 38:130–132.PubMed

20.

Edge JC, Outland JD, Dempsey JR, Callen JP: Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65–69.CrossRefPubMed

21.

• Sangle VS, Sangle SR, D’Cruz DP: Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis 2008, 67:723. This is one of several case reports to suggest a place for this agent.CrossRefPubMed

22.

Sereda D, Werth VP: Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol 2006, 142:70–72.CrossRefPubMed

23.

Nadiminti U, Arbiser JL: Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol 2005, 52(2 Suppl 1):17–19.CrossRefPubMed

24.

Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993–2000.CrossRefPubMed

25.

• Chung L, Genovese MC, Fiorentino DF: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007, 143:763–767. This report demonstrated moderate effects on the muscle disease but only limited response of the skin disease.CrossRefPubMed

Titel: Cutaneous Manifestations of Dermatomyositis and Their Management
verfasst von: Jeffrey P. Callen
Publikationsdatum: 01.06.2010
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 3/2010
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-010-0100-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cutaneous Manifestations of Dermatomyositis and Their Management

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Theories of the Pathogenesis of Inclusion Body Myositis

Cancer Therapies and Bone Health

The Societal Burden of Osteoporosis

Bone Changes and Fracture Risk in Individuals Infected With HIV

Update on the Assessment of Children with Juvenile Idiopathic Inflammatory Myopathy

Mechanical Factors and Bone Health: Effects of Weightlessness and Neurologic Injury

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin